|
1
|
Dimopoulos MA, Moulopoulos LA, Maniatis A
and Alexanian R: Solitary plasmacytoma of bone and asymptomatic
multiple myeloma. Blood. 96:2037–2044. 2000.PubMed/NCBI
|
|
2
|
Laubach J, Richardson P and Anderson K:
Multiple Myeloma. Annu Rev Med. 62:249–264. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Radbruch A, Muehlinghaus G, Luger EO,
Inamine A, Smith KGC, Dörner T and Hiepe F: Competence and
competition: The challenge of becoming a long-lived plasma cell.
Nat Rev Immunol. 6:741–750. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Azab AK, Runnels JM, Pitsillides C, Moreau
AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, et al:
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple
myeloma cells with the bone marrow microenvironment and enhances
their sensitivity to therapy. Blood. 113:4341–4351. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mead EJ, Maguire JJ, Kuc RE and Davenport
AP: Kisspeptins: A multifunctional peptide system with a role in
reproduction, cancer and the cardiovascular system. Br J Pharmacol.
151:1143–1153. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kotani M, Detheux M, Vandenbogaerde A,
Communi D, Vanderwinden JM, Poul EL, Brézillon S, Tyldesley R,
Suarez-Huerta N, Vandeput F, et al: The metastasis suppressor Gene
KiSS-1 encodes Kisspeptins, the natural ligands of the orphan g
protein-coupled receptor GPR54. J Biol Chem. 276:34631–34636.
2001.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lee JH, Miele ME, Hicks DJ, Phillips KK,
Trent JM, Weissman BE and Welch DR: KiSS-1, a novel human malignant
melanoma metastasis-suppressor gene. J Natl Cancer Inst.
88:1731–1737. 1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Takeda T, Kikuchi E, Mikami S, Suzuki E,
Matsumoto K, Miyajima A, Okada Y and Oya M: Prognostic role of
KiSS-1 and possibility of therapeutic modality of metastin, the
final peptide of the KiSS-1 gene, in urothelial carcinoma. Mol
Cancer Ther. 11:853–863. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhu C, Takasu C, Morine Y, Bando Y,
Ikemoto T, Saito Y, Yamada S, Imura S, Arakawa Y and Shimada M:
KISS1 associates with better outcome via inhibiting matrix
metalloproteinase-9 in colorectal liver metastasis. Ann Surg Oncol.
22:1516–1523. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jiang Y, Berk M, Singh LS, Tan H, Yin L,
Powell CT and Xu Y: KiSS1 suppresses metastasis in human ovarian
cancer via inhibition of protein kinase C alpha. Clin Exp
Metastasis. 22:369–376. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang H, Jones J, Turner T, He QP, Hardy S,
Grizzle WE, Welch DR and Yates C: Clinical and biological
significance of KISS1 expression in prostate cancer. Am J Pathol.
180:1170–1178. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Blake A, Dragan M, Tirona RG, Hardy DB,
Brackstone M, Tuck AB, Babwah AV and Bhattacharya M: G
protein-coupled KISS1 receptor is overexpressed in triple negative
breast cancer and promotes drug resistance. Sci Rep.
7(46525)2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Schmid K, Wang X, Haitel A, Sieghart W,
Peck-Radosavljevic M, Bodingbauer M, Rasoul-Rockenschaub S and Wrba
F: KiSS-1 overexpression as an independent prognostic marker in
hepatocellular carcinoma: An immunohistochemical study. Virchows
Archiv. 450:143–149. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rajkumar SV: Multiple myeloma: 2013 update
on diagnosis, risk-stratification, and management. Am J Hematol.
88:226–235. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hideshima T, Richardson P and Anderson KC:
Novel therapeutic approaches for multiple myeloma. Immunolol Rev.
194:164–176. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gay F and Palumbo A: Management of
disease- and treatment-related complications in patients with
multiple myeloma. Med Oncol. 27:43–52. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mahindra A, Laubach J, Raje N, Munshi N,
Richardson PG and Anderson K: Latest advances and current
challenges in the treatment of multiple myeloma. Nat Rev Clin
Oncol. 9:135–143. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Keats JJ, Fonseca R, Chesi M, Schop R,
Baker A, Chng WJ, Wier SV, Tiedemann R, Shi CX, Sebag M, et al:
Promiscuous mutations activate the noncanonical NF-kappaB pathway
in multiple myeloma. Cancer Cell. 12:131–144. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Annunziata CM, Davis RE, Demchenko Y,
Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W,
et al: Frequent engagement of the classical and alternative
NF-kappaB pathways by diverse genetic abnormalities in multiple
myeloma. Cancer Cell. 12:115–130. 2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Berenson JR, Ma HM and Vescio R: The role
of nuclear factor-kappaB in the biology and treatment of multiple
myeloma. Semin Oncol. 28:626–633. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Landowski TH, Olashaw NE, Agrawal D and
Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) is
associated with activation of NF-kappa B (RelB/p50) in myeloma
cells. Oncogene. 22:2417–2421. 2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Umezawa K: Possible role of peritoneal
NF-κB in peripheral inflammation and cancer: Lessons from the
inhibitor NF-κB (Review). Biomed Pharmacother. 65:252–259.
2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Tatetsu H, Okuno Y, Nakamura M, Matsuno F,
Sonoki T, Taniguchi I, Uneda S, Umezawa K, Mitsuya H and Hata H:
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappa B
inhibitor, induces apoptosis in multiple myeloma cells in an
IkappaBalpha-independent manner. Mol Cancer Ther. 4:1114–1120.
2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Horie R, Watanabe M, Okamura T, Taira M,
Shoda M, Motoji T, Utsunomiya A, Watanabe T, Higashihara M and
Umezawa K: DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and
enhances fludarabine effects on chronic lymphocytic leukemia cells.
Leukemia. 20:800–806. 2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Suzuki Y, Sugiyama C, Ohno O and Umezawa
K: Preparation and biological activities of optically active
dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor.
Tetrahedron. 60:7061–7066. 2004.
|
|
26
|
Ni H, Ergin M, Huang Q, Qin JZ, Amin HM,
Martinez RL, Saeed S, Barton K and Alkan S: Analysis of expression
of nuclear factor B (NF-kappa B) in multiple myeloma:
Down-regulation of NF-kappa B induces apoptosis. Br J Haematol.
115:279–286. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Barkette M and Gilmore TD: Control of
apoptosis by Rel/NF-kappaB transcription factors. Oncogene.
18:6910–6924. 1999.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pahl HL: Activators and target genes of
Rel/NF-kappaB transcription factors. Oncogene. 18:6853–6866.
1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Miguel JF, et al: Safety and efficacy of bortezomib in
high risk and elderly patients with relapsed multiple myeloma. Br J
Haematol. 137:429–435. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lonial S, Waller EK, Richardson PG,
Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S,
Torre C, et al: Risk factors and kinetics of thrombocytopenia
associated with bortezomib for relapsed, refractory multiple
myeloma. Blood. 106:3777–3784. 2005.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yamamoto M, Horie R, Takeiri M, Kozawa I
and Umezawa K: Inactivation of NF-kappaB components by covalent
binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine
residues. J Med Chem. 51:5780–5788. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Vega MI, Martinez-Paniagua M, Jazirehi AR,
Huerta-Yepez S, Umezawa K, Martinez-Maza O and Bonavida B: The
NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise
rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by
various chemotherapeutic drugs. Leuk Lymphoma. 49:1982–1994.
2008.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ando Y, Sato Y, Kudo A, Watanabe T,
Hirakata A, Okada AA, Umezawa K and Keino H: Anti-inflammatory
effects of the NF-κB inhibitor dehydroxymethylepoxyquinomicin on
ARPE-19 cells. Mol Med Rep. 22:582–590. 2020.PubMed/NCBI View Article : Google Scholar
|
